NovaBay Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards

By December 21, 2017

EMERYVILLE, Calif. (December 21, 2017) – NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova lid and lash hygiene for the domestic eye care market, announces that it has regained compliance with NYSE American continued listing standards.

“We view the ability to maintain compliance with the NYSE as a vote of confidence from shareholders in our Avenova commercialization strategy and the prospect for NovaBay going forward,” said Mark M. Sieczkarek, NovaBay’s President and CEO. “We are positioning for another year of growth and execution on our commercial strategy supported by funds from our previously announced financings when completed.”

On May 16, 2017, NovaBay received notice that the Company was out of compliance with Section 1003(a)(iii) of the NYSE American Company Guide. On September 14, 2017, NovaBay received notice that it was out of compliance with Section 1003(a)(ii) of the NYSE American Company Guide. Both NYSE American standards pertained to stockholders’ equity.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.

Forward-Looking Statements
This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding any potential benefit or deleterious effect due to the transition in management, inclusive of any possible effect that would have generally on the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in manufacturing, distributing, and selling the Company’s products, unexpected adverse side effects or inadequate therapeutic efficacy of our product, the uncertainty of patent protection for the Company’s intellectual property, and any potential regulatory problems. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.


Socialize and Stay informed on NovaBay’s progress:
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website

NovaBay Contacts
For NovaBay Avenova purchasing information:
Please Call us toll free: 1-800-890-0329 or email

From the Company
Jack McGovern
Chief Financial Officer

Investor Contact
Jody Cain